News - Cellvizio - Aug 4, 2023

Mauna Kea Technologies Announces the Transfer of its Shares on the Euronext Growth Paris Market Will Be Effective August 8 2023

Paris and Boston, August 4, 2023 – 8:00 a.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that the transfer of its ordinary shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility will be effective on August 8, 2023. 

The application for admission of Mauna Kea Technologies ordinary shares to the Euronext Growth Paris market was approved by the Euronext Admissions Committee at its meeting on August 3, 2023. 

This transfer, which was authorized by the General Meeting of Mauna Kea Technologies shareholders held on June 2, 2023, will enable the Company to be listed on a market offering a flexible regulatory framework tailored to its size and market capitalization, while reducing certain operating constraints specific to the Euronext Paris market. The transfer to Euronext Growth Paris should also simplify the Company's operations and reduce the costs associated with its listing, while enabling it to continue to benefit from the advantages of the financial markets. 

Mauna Kea Technologies will continue to deliver accurate, precise and truthful information, disclosing any insider information concerning the Company, in accordance with the provisions of Regulation (EU) No. 596/2014 of April 16th, 2014 on market abuse ("MAR"). 

The Information Document drawn up in connection with this transfer is available on the Company's website ( under the "Investors" section. 

The ISIN code for Mauna Kea Technologies shares remains unchanged (FR0010609263), and the mnemonic code becomes ALMKT. Mauna Kea Technologies shares remain eligible for the PEA-PME scheme.

The operation was performed with Allegra Finance as the listing sponsor.